Featured Stories
Synaffix’s Serial Dealmaker On ADC Platform Success And Expanding Into Gene Therapy
Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.

Finger On The Pulse: The State Of Biopharma Leadership
In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

How To Be An Early-Stage Biotech CEO In Challenging Times
The ongoing downturn is making early-stage biotech leaders work harder to gain funding – but new technology, business focus and better working practices could help them achieve success.
Growth Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Growth
Deal-Making In 2023: Pharma Finds Value In Flexibility
Restricted financial avenues raised many open questions at the recent LSX World Congress about the kind of deals that will shape biopharma pipelines in the coming 12-18 months.
Snapshot: March Highlights
A selection of articles you may have missed from March 2023, including discussion of the benefits and risks of both CAR-T and NK cell therapies, insights into how companies can source financing when VC cash is scarce, and a highlight on Pfizer's mammoth purchase of Seagen.
Uzbekistan To Implement Large Pharma Projects
Uzbekistan is the most populous country in Central Asia with 36 million people. The country has the only plant in Central Asia specializing in insulin production for the treatment of diabetes. Uzbek authorities aim to develop 90 pharma projects worth $1.2bn by 2026.
Innovation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Innovation
Fostering a Culture of Innovation, From Evolutionary To Revolutionary
Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.
Alife Health Leverages AI For IVF To Increase Access To Care And Chances Of Success
One in eight couples in the US are struggling to get pregnant. Alife Health’s CEO Paxton Maeder-York believes that by leveraging artificial intelligence for use in IVF fertility clinics, he can help shape a future where more people have a better chance of starting families at a lower cost and higher rate of success.
Ovid Therapeutics: Seeking Innovation In Epilepsy Treatment
Rising Leader Julia Tsai wants to see Ovid Therapeutics become a market leading epilepsy company that listens to the needs of patients and develops innovative drugs to treat a spectrum of epileptic indications and symptoms.
Rising Leaders
In Vivo’s 2023 Rising Leaders: Healthcare Innovators At The Top Of Their Game
The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.
At The Forefront Of Regulatory Change – BIVDA’s Ashleigh Batchen
In Vivo Rising Leader Ashleigh Batchen has packed a lot of experience of medical device diagnostic regulatory issues into a few short years at the British In Vitro Diagnostics Association and before that the UK MHRA. Her advocacy offers vital support to the IVD industry at the busiest time in UK – and EU – regulatory history.
Leadership Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Leadership
Wave Of New Leaders Could Reshape Generics Industry
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
Fostering a Culture of Innovation, From Evolutionary To Revolutionary
Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.
The E in ESG: Thermo Fisher On Why The ‘How’ Is More Important Than The ‘When’
Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.
Market Access Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
In Saudi Arabia, A Vision Of Healthcare Spurs Growth
As the Kingdom of Saudi Arabia reduces its dependence on oil as an export, one sector it is building up is the life sciences industry. The government is encouraging global companies to manufacture and invest domestically and they are improving their regulatory system and working with local players to enhance access to patients.
The E In ESG: Sustainability Goals Do Not Exempt Companies From Antitrust Compliance
Regulatory interventions are the preferred route for ensuring sustainability compliance, says the OECD. Legal firm CMS notes that some ESG objectives may be in contravention of antitrust law. The EU is preparing guidelines on horizontal competition with a renewed focus on sustainability.
‘Fail Quickly, Succeed Quickly’ – BioWales Profiles Value Proposition For Medtech Innovation
New policy initiatives and “can do” networking openness in Wales are persuading medtech and healthtech innovators to consider the merits of locating in Great Britain’s smallest home nation.
Market Intelligence Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Intelligence
Dealmaking Quarterly Statistics, Q1 2023
During Q1, biopharma merger and acquisition deal value reached $51.9bn and drew in $38.1bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $2.7bn.
Deals Shaping The Medical Industry, April 2023
In Vivo's deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in March 2023. Data provided by Biomedtracker.
Pear Bankruptcy Filing Highlights Reimbursement Barriers for Digital Therapeutics
Pear Therapeutics, Inc. filed for Chapter 11 bankruptcy in April, saying that it had laid off about 92% of its staff but would still pursue a sale of the company or its assets. Health care insiders tell AIS Health, a division of MMIT, that the announcement by one of the pioneers in the prescription digital therapeutics industry highlights the challenges such companies face getting their products reimbursed. The difficulties are exacerbated by investors being wary of backing companies that promise future growth but have yet to turn a profit.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.